Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸ : 2020-08-07±³À°ÀÏÀÚ : 2020-08-07
±³À°Àå¼Ò : ºÎ»ê, º¤½ºÄÚ(Á¦2Àü½ÃÀå)
±³À°ÁÖÁ¦ :
Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Á¤º°
¿¬¶ôó : 02-565-3350
À̸ÞÀÏ :
ksh@koreanhypertension.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, ½Å°æ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ¾à¸®ÇÐ, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 22 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø(6¸¸¿ø),Á¤È¸¿ø ¿Ü(8¸¸¿ø), Àü°øÀǹױâŸ(4¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇÑ¿ø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á) *ÇöÀåµî·Ï:ȸ¿ø(8¸¸¿ø),ºñȸ¿ø(10¸¸¿ø), Àü°øÀǹױâŸ(5¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇпø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-07 Room A 09:00~10:00 Role of the 3rd generation beta-blockers in the future treatment for hypertension Á¶±¸¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 09:00~09:15 Recent Guidelines on Lifestyle Modifications ±èÈ¿Àº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 09:15~09:30 Dietary Behavior to Prevent and Treatment Hypertension ±èº´±Ô(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 09:30~09:45 Individual Exercise Strategy for Lowering Blood Pressure ¹ÚÁ¤ÁØ(ºÎ»ê´ëÇб³)
±³À°½Ã°£ 08-07 Room C 09:45~10:00 Obesity Correction Effects According to Hypertension Stage ±è±âÇö(¿ï»êÀÇ´ë)
Åä·Ð 08-07 Room C 10:00~10:10 Panel Discussion Á¤Çý¹®, Çã¶õ(°æÈñÀÇ´ë, ÇѾçÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 10:30~10:45 Blood Pressure and Kidney Donor (Nephrectomy) ±è¼öÇö(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 10:45~11:00 Blood Pressure and Kidney Transplant Recipient ¼Û»óÇå(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 11:00~11:15 Blood Pressure and Valvular Heart Disease (Natural Prognosis) ¼Áö¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 11:15~11:30 Blood Pressure and Valve Surgery (OP Outcome) ±è´ëÈñ(¿ï»êÀÇ´ë)
Åä·Ð 08-07 Room A 11:30~11:40 Panel Discussion ±è¹Ì³ª, ±è¹Î°ü, ±èÇüÀ±(°í·ÁÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 10:30~10:45 Glycemic Effect of GLP-1 RA and Review of Recent Guideline Focused on GLP- 1RA ±ÇÇõ»ó(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 10:45~11:00 Impact of GLP-1 RA on Blood Pressure ÀÌÈñ¼±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 11:00~11:15 Cardiovascular Effect and Potential Mechanism of Reducing Cardiovascular Mortality of GLP-1 RA Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 11:15~11:30 Microvascular Outcomes of GLP-1RA (or rRenal Effect of GLP-1 RA) Á¤Àΰæ(°æÈñÀÇ´ë)
Åä·Ð 08-07 Room B 11:30~11:40 Panel Discussion ±è¹Ì³ª, ±è¹Î°ü, ±èÇüÀ±(°í·ÁÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 10:30~10:45 Ambulatory Blood Pressure Monitoring in Heart Failure Patients [Eng] ±è°æÁø(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 10:45~11:00 Ambulatory Blood Pressure Monitoring in Stroke Patients [Eng] ±è¹üÁØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 11:00~11:15 Ambulatory Blood Pressure Monitoring in Chronic Kidney Disease Patients [Eng] Â÷¶õÈñ(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 08-07 Room C 11:15~11:30 Ambulatory Blood Pressure Monitoring in Diabetes or Autonomic Dysfunction [Eng] Yuqing Zhang(China)
Åä·Ð 08-07 Room C 11:30~11:40 Panel Discussion ¹Ú°æÀÏ, ÀÌÁ¤Ç¥, Á¶ÁØȯ(µ¿¾ÆÀÇ´ë, ¼¿ïÀÇ´ë, Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 11:40~12:00 Approaches for the Medical Management of Resistant Hypertension ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 12:00~12:20 What is your choice for CV risk reduction? (Aspirin or Statin) ¹÷°æÀÏ(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 11:40~12:00 Clinical Considerations for Use of ARB+CLD Combination Therapy in Hypertension ±è±¤ÀÏ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 12:00~12:20 Angiotensin Receptor Blocker Based Blood Pressure Control in Hypertensive patients with Left Ventricular Hypertrophy ¹®Á¤±Ù(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 11:40~12:00 The Trend of New Technology of Cardiovascular Field Silicon Valley [Eng] Fumiaki lkeno(Stanford University, US)
±³À°½Ã°£ 08-07 Room C 12:00~12:20 The Emerging Era of Wearable Cuffless Blood Pressure Monitors [Eng] George Stergiou(Greece reorge(Greece)
±³À°½Ã°£ 08-07 Room C 12:20~12:30 The Role of Monitoring Ambulatory Central Blood Pressure [Eng] Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 12:30~12:40 The Role of Monitoring of Home Blood Pressure [Eng] Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë)
Åä·Ð 08-07 Room C 12:40~12:50 Panel Discussion Á¶Á¤¼±, ¹Ú»ó¹Î, ±è°æÁø(°¡Å縯ÀÇ´ë, À»ÁöÀÇ´ë, ÀÌÈÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 12:50~13:05 Recent Prevalence of High Risk Pregnant Women ¹Ú¼º¹Ì(°í·ÁÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 13:05~13:20 What Kinds of Problem Can Hypertension Cause during Pregnancy? À̵¿Çü(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 13:20~13:35 Current Status of Anti-Hypertensive Drug Availability for Pregnant Women in Korea ½ÅÁøÈ£(ÇѾçÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 13:35~13:50 Practical Approach for Perinatal BP Control ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë)
Åä·Ð 08-07 Room A 13:50~14:05 Panel Discussion À̹ÎÈ£, Á¶ÁØȯ, ÃÖÁ¤Çö(¼øõÇâÀÇ´ë, Áß¾ÓÀÇ´ë, ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 12:50~13:05 Importance of Risk Factor Variability in Disease Prediction ±èÇöâ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 13:05~13:20 Statistical Approach for Assessing BP Variability ±èµ¿¿í(±¹¹Î°Ç°º¸Çè°ø´Ü)
±³À°½Ã°£ 08-07 Room B 13:20~13:35 Machine Learning Approach for Assessing BP variability ¾È¼ºº¹(ÀÌÈ¿©´ëÀ¶ÇÕº¸°ÇÇаú)
±³À°½Ã°£ 08-07 Room B 13:35~13:50 Analysis of Long-term BP Variability with Real World Data °´ë¿ë(¿¬¼¼¿øÁÖÀÇ´ë)
Åä·Ð 08-07 Room B 13:50~14:05 Panel Discussion ±æÈ«·®, ¹éÀç¼÷, Á¶µ¿Çõ(Ãæ³²ÀÇ´ë, ¿ï»êÀÇ´ë, ¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 12:50~13:05 How to Manage for Resistant Hypertension in Pregnancy [Eng] Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 13:05~13:20 Baroreflex Stimulation for Treating Resistant Hypertension [Eng] ±è¹Ì³ª(°í·ÁÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 13:20~13:35 Exercise as a Tool for Resistant Hypertension Management: Current Insights [Eng] ÃÖÁøÈ£(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 13:35~13:50 Novel Catheter-based Renal Denervation System of Cryoablation (Cryo-RDN) for Resistant Hypertension [Eng] Junbo Ge(China)
Åä·Ð 08-07 Room C 13:50~14:05 Panel Discussion ±è¼ÛÀÌ, Á¶ÀÎÁ¤(Á¦ÁÖÀÇ´ë, ÀÌÈÀÇ´ë)
ÈÞ½Ä 08-07 14:05~14:30 Moderated poster with coffee break ()
±³À°½Ã°£ 08-07 Room A 14:35~15:05 Comprehensive management of hypertension in high risk patients ±è±¤ÀÏ(¼¿ïÀÇ´ë)
Åä·Ð 08-07 Room A 15:05~15:30 Discussion ()
±³À°½Ã°£ 08-07 Room B 14:30~15:00 From ASCOT to ASCOT Legacy: the Long-term Benefit for CV Patients. ¾çÇö¼÷(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 15:00~15:30 What could be optimal strategy to treat HTN & DYS in DM patients ±è¹Ì°æ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 14:30~14:45 Epidemiology and Pathophysiology of Sleep Apnea À±ÇöÁÖ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 14:45~15:00 Cardiovascular Events: Focused on Resistant Hypertension ¹Ú»ó¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 15:00~15:15 15 Interpretation of Polysomnography Á¶±Ô¼·(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 15:15~15:30 Management of Patients with Sleep Apnea ±èµ¿±Ô(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 15:30~15:45 Updates in Therapeutic Approach of Atherosclerosis ¹Ú¿µ¹Ì(ÀÌÈ¿©´ë)
±³À°½Ã°£ 08-07 Room A 15:45~16:00 Role of Inflammation and Immunity in Hypertension ±èÀΰâ(°æºÏÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 16:00~16:15 Redox Regulation of Vascular Inflammation Àüº´È(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 16:15~16:30 Renal Fibrosis in Alport Syndrome ¹èÀºÈñ(Àü³²ÀÇ´ë)
Åä·Ð 08-07 Room A 16:30~16:45 Panel Discussion Â÷´ë·æ(°æÈñÀÇ´ë, °í·ÁÀÇ´ë, Ãæ³²ÀÇ´ë, °í·ÁÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 15:30~15:45 Brain-Heart Axis: Cerebrogenic Cardiomyopathy ¼¿ì±Ù(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 15:45~16:00 Hypertension and Cerebral Artery Dissection/Aneurysm ±è¹üÁØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 16:00~16:15 Hypertension and Cerebral Small Vessel Disease ÀÓÀ缺(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 16:15~16:30 New Evidence of Hypertension Control on Stroke À¯ÁØ»ó(±¹¹Î°Ç°º¸Çè°ø´Ü)
Åä·Ð 08-07 Room B 16:30~16:45 Panel Discussion °ÁöÈÆ, ±èÁ¤¹Î, ÃÖ°È£(¼¿ïÀÇ´ë, Áß¾ÓÀÇ´ë, Àü³²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 15:30~15:45 Proper BP Measurement Technique for BP Variability Á¤¿ì¹é(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 15:45~16:00 BP Variability in Elderly Hypertensive Patients ÃÖ¼ºÀÏ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 16:00~16:15 BP Variability in Stroke and Cognitive Decline ±èÇзÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 16:15~16:30 Therapeutic Management for Patients with BP Variability ÁøÁ¤¿¬(ÁøÁ¤¿¬)
Åä·Ð 08-07 Room C 16:30~16:45 Panel Discussion ¹Ú»ó¹Î, ¹Ú¿ëÇö, Á¶ÀºÁ¤(À»ÁöÀÇ´ë, ºÎ»êÀÇ´ë, ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 16:45~17:00 SGLT2 Inhibitor and Blood Pressure in CKD À¯ÅÂÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 17:00~17:15 Neprilysin Inhibitors and Blood Pressure in CKD ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 17:15~17:30 CCB and Renoprotection in CKD ±èÈ¿Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room A 17:30~17:45 Beta Blocker and Renoprotection in CKD ¹éÁøÇõ(°è¸íÀÇ´ë)
Åä·Ð 08-07 Room A 17:45~18:00 Panel Discussion ±è¼ö¿Ï, À¯°æµ·, À̵¿¿ø(Àü³²ÀÇ´ë, ¿ï»êÀÇ´ë, ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 16:45~17:00 Pro –±èÇöÁø(ÇѾçÀÇ´ë) ±èÇöÁø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 17:00~17:15 Cons – ±è´ëÈñ(¿ï»êÀÇ´ë) ±è´ëÈñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 17:15~17:30 Rebuttal Pro – ¹Ú¿ëÇö(ºÎ»êÀÇ´ë) ¹Ú¿ëÇö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-07 Room B 17:30~17:45 Rebuttal Cons - Á¤Çý¹®(°æÈñÀÇ´ë) Á¤Çý¹®(°æÈñÀÇ´ë)
Åä·Ð 08-07 Room B 17:45~18:00 Panel Discussion ±è±âÇö(¿ï»êÀÇ´ë), Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë), Á¶ÀÎÁ¤(ÀÌÈÀÇ´ë) ±è±âÇö, Á¤¹ÌÇâ, Á¶ÀÎÁ¤(¿ï»êÀÇ´ë, ÇѸ²ÀÇ´ë, ÀÌÈÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 16:45~17:00 Epidemiology of Prehypertension in Korea - Hyeon Chang Kim_±èÇöâ(Yonsei Univ.) [Eng] ±èÇöâ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08-07 Room C 17:00~17:15 National Governmental Policy to Enhance HT Control in Malaysia -Abdul Rashid Rahman (Malaysia) [Eng] Abdul Rashid Rahman(Malaysia)
±³À°½Ã°£ 08-07 Room C 17:15~17:30 Optimal Management Strategy in Prehypertension - Sang Hyun Ihm_ÀÓ»óÇö(Catholic Univ) [Eng] ÀÓ»óÇö(Catholic Univ)
±³À°½Ã°£ 08-07 Room C 17:30~17:45 Lifestyle Modification in Prehypertension - Yook Chin Chia(Malaysia) [Eng] Yook Chin Chia(Malaysia)
Åä·Ð 08-07 Room C 17:45~18:00 Panel Discussion ¹Ú¼ºÇÏ, ¼º±âö, Abdul Rashid Rahman(¿¬¼¼ÀÇ´ë, ¼º±Õ°üÀÇ´ë, Malaysia)